

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to investigate the Safety and Efficacy of ABT-494 Given with Methotrexate (MTX) in Subjects with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Anti-TNF Biologic Therapy

Published: 24-02-2014

Last updated: 20-04-2024

The primary objective is to compare the safety and efficacy of multiple doses of ABT-494 versus placebo in moderately to severely active RA subjects on stable background MTX therapy with inadequate response or intolerance to anti-TNF biologic...

Ethical review	Approved WMO
Status	Will not start
Health condition type	Musculoskeletal and connective tissue disorders congenital
Study type	Interventional

Summary

ID

NL-OMON40747

Source

ToetsingOnline

Brief title

M13-550, ABT-494

Condition

- Musculoskeletal and connective tissue disorders congenital

Synonym

rheumatic diseases, Rheumatoid Arthritis

Research involving

Human

Sponsors and support

Primary sponsor: AbbVie Deutschland GmbH & Co. KG

Source(s) of monetary or material Support: Industry

Intervention

Keyword: ABT-494, M13-550, phase 2, Rheumatoid Arthritis (RA)

Outcome measures**Primary outcome**

Efficacy:

The primary endpoint of this study is the ACR20 response rate at Week 12. ACR20 response rate will be determined based on 20% or greater improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and ≥ 3 of the 5 measures of Patient's Assessment of Pain (VAS), Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity, Patient's Assessment of Disability (HAQ-DI) or hsCRP. The secondary endpoints of this study are ACR50/70 response rates at Week 12, the proportion of subjects achieving low disease activity (LDA) ($2.6 \leq \text{DAS28 [CRP]} < 3.2$) or clinical remission (CR) ($\text{DAS28 [CRP]} < 2.6$), and the proportion of subjects achieving CR ($\text{DAS28 [CRP]} < 2.6$) at Week 12.

Pharmacokinetics:

For all subjects, PK trough samples will be collected at each visit beginning

on Day 1 (Baseline) through Week 12. For 30% of subjects, in addition to trough PK samples at each visit, PK samples will be collected on Day 1 (Baseline) and Week 8 at 1, 2, and 3 hours post-morning dose.

Safety:

Safety evaluations include adverse event monitoring, physical examinations, vital sign measurements, electrocardiogram, and clinical laboratory testing (hematology, chemistry, and urinalysis) as a measure of safety and tolerability. Toxicity management guidelines are provided in the protocol.

Secondary outcome

Secondary Efficacy Variables:

- * ACR50 and ACR70 response rates at Week 12
- * Proportion of subjects achieving low disease activity (LDA) ($2.6 \leq \text{DAS28}$ [CRP] < 3.2) or clinical remission (CR) (DAS28 [CRP] < 2.6) at Week 12.
- * Proportion of subjects achieving CR based on DAS28 [CRP] < 2.6 at Week 12.

Study description

Background summary

ABT-494 is being developed for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA). The enhanced selectivity of ABT-494 may offer an improved benefit:risk profile in patients with RA.

Study objective

The primary objective is to compare the safety and efficacy of multiple doses of ABT-494 versus placebo in moderately to severely active RA subjects on stable background MTX therapy with inadequate response or intolerance to

anti-TNF biologic therapy.

Study design

This is a Phase 2, randomized, double-blind, parallel-group, placebo-controlled multicenter study comparing the safety and efficacy of multiple twice daily (BID) doses of ABT-494 versus placebo administered for 12 weeks in subjects with moderately to severely active RA who have shown an inadequate response or intolerance to anti-TNF biologic treatment(s).

Intervention

Subjects will be randomized in a 1:1:1:1:1 fashion to one of 4 doses of ABT-494 or placebo, all administered with stable background MTX therapy.

The following are the treatment groups:

Group 1: take twice a day one capsule of ABT-494 3 mg BID

Group 2: take twice a day one capsule of ABT-494 6 mg BID

Group 3: take twice a day one capsule of ABT-494 12 mg BID

Group 4: take twice a day one capsule of ABT-494 18 mg BID

Group 5: take twice a day one capsule of Placebo BID

Study burden and risks

The prevalence of Rheumatoid arthritis (RA) in the general population is approximately 1%, and increases with age in both genders, with women being more prone for developing RA than men. RA subjects who inadequately responded to or are unable to tolerate an anti-TNF therapy are a subgroup of patients with significant unmet medical need. We would like to use ABT-494 for this patient population. The information that is obtained during this study is useful scientifically and thus be helpful to others with the same condition in the future.

Contacts

Public

AbbVie Deutschland GmbH & Co. KG

Knollstrasse 50

Ludwigshafen 67061

DE

Scientific

AbbVie Deutschland GmbH & Co. KG

Knollstrasse 50
Ludwigshafen 67061
DE

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

1. Adult male or female, at least 18 years old.;2. Diagnosed with RA based on either the 1987-revised American College of Rheumatology (ACR) classification criteria or the 2010 American College of Rheumatology/European League against Rheumatism (ACR/EULAR) criteria for ≥ 3 months.;3. Subjects must have been receiving oral or parenteral MTX therapy ≥ 3 months and on a stable prescription of 7.5 to 25 mg/week for at least 4 weeks prior to initiating the study drug. Subjects should also be on a stable dose of folic acid (or equivalent) for at least 4 weeks prior to initiating the study drug. Subjects should continue with their stable doses of MTX and folic acid throughout the study.;4. Subjects have been treated with 1 or 2 anti-TNF biologics for ≥ 3 months but continue to exhibit active RA, or had to discontinue due to intolerability or toxicity. In addition, subjects may have received up to 1 non-anti-TNF biologic (e.g., abatacept, rituximab, anakinra, or tocilizumab) prior to Screening.;5. Have active RA as defined by the following minimum disease activity criteria:

- ≥ 6 swollen joints (based on 66 joint counts) at Screening and Baseline Visits.
- ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.
- hs-CRP $>$ Upper Limit of Normal (ULN) OR positive for both rheumatoid factor and anti-CCP antibody.

Exclusion criteria

A subject will be excluded from the study if he/she meets any of the following criteria:

1. Prior exposure to JAK inhibitor (e.g., tofacitinib, baricitinib).
2. Receipt of any investigational drug of chemical or biologic nature within a minimum of 30 days or 5 half-lives of the drug (whichever is longer) prior to initiating the study drug.
3. Current or expected need of other immunosuppressant medications, except MTX. Use of oral intake of > 10 mg prednisone/day or equivalent corticosteroid therapy.
4. Screening laboratory values meeting the following criteria:
 - Serum aspartate transaminase (AST) or alanine transaminase (ALT) > 1.5 × ULN
 - Estimated glomerular filtration rate (eGFR) by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula < 40 mL/min/1.73 m²
 - Total white blood cell count (WBC) < 3,000/μL
 - Absolute neutrophil count (ANC) < 1,200 /μL
 - Platelet count < 100,000/μL
 - Absolute lymphocytes count < 750/μL
 - Hemoglobin < 9 gm/dL

Study design

Design

Study phase:	2
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

Recruitment

NL	
Recruitment status:	Will not start
Enrollment:	12
Type:	Anticipated

Medical products/devices used

Product type:	Medicine
Brand name:	ABT-494
Generic name:	ABT-494

Ethics review

Approved WMO	
Date:	24-02-2014
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO	
Date:	30-07-2014
Application type:	First submission
Review commission:	METC Amsterdam UMC
Approved WMO	
Date:	14-08-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO	
Date:	01-10-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO	
Date:	06-10-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO	
Date:	27-10-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC
Approved WMO	
Date:	04-12-2014
Application type:	Amendment
Review commission:	METC Amsterdam UMC

Approved WMO
Date: 16-01-2015
Application type: Amendment
Review commission: METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2013-002358-57-NL
ClinicalTrials.gov	NCT01960855
CCMO	NL47690.018.14